Gulf Pharmaceutical Industries P.S.C Future Growth

Future criteria checks 0/6

Gulf Pharmaceutical Industries P.S.C is forecast to grow revenue at 4.3% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	13.5%
Revenue growth rate	4.3%
Future return on equity	10.20%
Analyst coverage	Low
Last updated	19 May 2025

Recent future growth updates

Recent updates

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Apr 28

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Mar 25

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Oct 16

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14

Earnings and Revenue Growth Forecasts

ADX:JULPHAR - Analysts future estimates and past financials data (AED Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	1,496	N/A	N/A	N/A	1
12/31/2026	1,425	N/A	86	171	1
12/31/2025	1,359	N/A	251	340	1
3/31/2025	1,335	22	129	165	N/A
12/31/2024	1,313	15	192	245	N/A
9/30/2024	1,250	11	195	250	N/A
6/30/2024	1,199	-22	154	206	N/A
3/31/2024	1,160	-62	115	164	N/A
12/31/2023	1,278	-80	67	94	N/A
9/30/2023	1,587	-128	-9	42	N/A
6/30/2023	1,637	-85	-54	-2	N/A
3/31/2023	1,652	-38	-42	16	N/A
12/31/2022	1,616	-34	-46	19	N/A
9/30/2022	1,651	-28	-68	-7	N/A
6/30/2022	1,598	0	13	75	N/A
3/31/2022	1,398	64	10	59	N/A
12/31/2021	1,143	47	2	46	N/A
9/30/2021	858	-104	-42	-21	N/A
6/30/2021	682	-138	-117	-101	N/A
3/31/2021	632	-203	-145	-125	N/A
12/31/2020	573	-247	-184	-168	N/A
9/30/2020	540	-184	-238	-229	N/A
6/30/2020	376	-377	-240	-224	N/A
3/31/2020	295	-472	-179	-159	N/A
12/31/2019	302	-494	-119	-85	N/A
9/30/2019	265	-957	10	62	N/A
6/30/2019	388	-840	31	84	N/A
3/31/2019	567	-716	87	145	N/A
12/31/2018	720	-612	N/A	179	N/A
9/30/2018	928	-20	N/A	136	N/A
6/30/2018	1,106	80	N/A	200	N/A
3/31/2018	1,085	70	N/A	113	N/A
12/31/2017	1,155	95	N/A	81	N/A
9/30/2017	1,293	142	N/A	234	N/A
6/30/2017	1,275	145	N/A	234	N/A
3/31/2017	1,418	178	N/A	264	N/A
12/31/2016	1,455	212	N/A	268	N/A
9/30/2016	1,391	205	N/A	261	N/A
6/30/2016	1,407	215	N/A	242	N/A
3/31/2016	1,391	214	N/A	235	N/A
12/31/2015	1,470	230	N/A	183	N/A
9/30/2015	1,510	226	N/A	117	N/A
6/30/2015	1,449	235	N/A	161	N/A
3/31/2015	1,443	228	N/A	96	N/A
12/31/2014	1,388	204	N/A	40	N/A
9/30/2014	1,382	224	N/A	131	N/A
6/30/2014	1,427	231	N/A	-22	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if JULPHAR's forecast earnings growth is above the savings rate (14.8%).

Earnings vs Market: Insufficient data to determine if JULPHAR's earnings are forecast to grow faster than the AE market

High Growth Earnings: Insufficient data to determine if JULPHAR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: JULPHAR's revenue (4.3% per year) is forecast to grow slower than the AE market (6.8% per year).

High Growth Revenue: JULPHAR's revenue (4.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: JULPHAR's Return on Equity is forecast to be low in 3 years time (10.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/22 18:58
End of Day Share Price	2025/05/22 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gulf Pharmaceutical Industries P.S.C. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rim Ben Salah Gharbi	AlphaMena
null RESEARCH DEPARTMENT	Prime Research

Gulf Pharmaceutical Industries P.S.C Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to د.إ1.57

Recent updates

First quarter 2025 earnings released: EPS: د.إ0.018 (vs د.إ0.002 in 1Q 2024)

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Screens Well But There Might Be A Catch

Statutory Profit Doesn't Reflect How Good Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Earnings Are

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2025

New major risk - Financial position

Full year 2024 earnings released: EPS: د.إ0.013 (vs د.إ0.09 loss in FY 2023)

KELIX Bio Limited completed the acquisition of DiabTec LLC from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

An undisclosed buyer agreed to acquire DiabTec LLC from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

Third quarter 2024 earnings released: د.إ0.006 loss per share (vs د.إ0.034 loss in 3Q 2023)

Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified

Second quarter 2024 earnings released

Gulf Pharmaceutical Industries P.S.C. to Report Q2, 2024 Results on Aug 14, 2024

Now 21% overvalued

First quarter 2024 earnings released: EPS: د.إ0.002 (vs د.إ0.003 loss in 1Q 2023)

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: د.إ0.09 loss per share (vs د.إ0.029 loss in FY 2022)

Full year 2023 earnings released: د.إ0.087 loss per share (vs د.إ0.029 loss in FY 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Third quarter 2023 earnings released: د.إ0.034 loss per share (vs د.إ0.003 profit in 3Q 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Second quarter 2023 earnings released: د.إ0.037 loss per share (vs د.إ0.003 profit in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: EPS and revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.028 in 3Q 2021)

Gulf Pharmaceutical Industries P.S.C. to Report Q3, 2022 Results on Nov 09, 2022

Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer

Second quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.059 in 2Q 2021)

First quarter 2022 earnings: Revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. to Report Q1, 2022 Results on May 13, 2022

Price target decreased to د.إ1.57

Less than half of directors are independent

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Third quarter 2021 earnings released: EPS د.إ0.028 (vs د.إ0.003 loss in 3Q 2020)

GlobalOne Healthcare acquired Gulf Inject LLC from Gulf Pharmaceutical Industries P.S.C.

Second quarter 2021 earnings released: EPS د.إ0.059 (vs د.إ0.028 loss in 2Q 2020)

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) completed the acquisition of remaining 60% stake in Planet Pharmacies LLC from KAMCO Investment Company K.S.C.P. (KWSE:KAMCO) and others.

An unknown buyer agreed to acquire 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) agreed to acquire a 60% stake in Planet Pharmacies LLC.

First quarter 2021 earnings released: د.إ0.026 loss per share (vs د.إ0.094 loss in 1Q 2020)

Full year 2020 earnings released: د.إ0.28 loss per share (vs د.إ0.75 loss in FY 2019)

New 90-day low: د.إ1.26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

New 90-day high: د.إ1.55

Radiant Pharmaceuticals Limited acquired Julphar Bangladesh Ltd from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) and RAK Pharmaceuticals Pvt. Ltd. for BDT 1.4 billion.